Patents by Inventor Mark Edward Zak

Mark Edward Zak has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230016791
    Abstract: wherein R1, R2, R3, R4, R5 and R6 are as defined herein, and salts thereof that are useful as JAK kinse inhibitors are described herein. Also provided are pharmaceutical compositions that include such a JAK inhibitor and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.
    Type: Application
    Filed: August 24, 2022
    Publication date: January 19, 2023
    Applicant: Genentech, Inc.
    Inventors: Mark Edward Zak, Naomi S. Rajapaksa, Yun-Xing Cheng, Jessica Marie Grandner, Daniel G.M. Shore, Marian C. Bryan
  • Patent number: 11453671
    Abstract: Compounds of formula (I) wherein R1, R2, R3, R4, R5 and R6 are as defined herein, and salts thereof that are useful as JAK kinse inhibitors are described herein. Also provided are pharmaceutical compositions that include such a JAK inhibitor and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.
    Type: Grant
    Filed: June 16, 2020
    Date of Patent: September 27, 2022
    Assignee: Genentech, Inc.
    Inventors: Mark Edward Zak, Naomi S. Rajapaksa, Yun-Xing Cheng, Jessica Grandner, Daniel G. M. Shore, Marian C. Bryan
  • Publication number: 20220204517
    Abstract: Compounds of Formula (00A) and salts thereof, wherein R1, R2 R3, R4 and n are defined herein, are useful as inhibitors of one or more Janus kinases. Also provided are pharmaceutical compositions that include a compound of Formula (00A) and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.
    Type: Application
    Filed: March 9, 2022
    Publication date: June 30, 2022
    Applicant: Genentech, Inc.
    Inventors: Yun-Xing Cheng, Paul Gibbons, Terry Kellar, Wei Li, Rohan Mendonca, Po-wai Yuen, Mark Edward Zak, Lei Zhang
  • Publication number: 20220106322
    Abstract: Compounds and salts thereof that are useful as JAK kinase inhibitors are described herein. Also provided are pharmaceutical compositions that include such a JAK inhibitor and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.
    Type: Application
    Filed: December 16, 2021
    Publication date: April 7, 2022
    Applicant: Genentech, Inc.
    Inventors: Mark Edward Zak, Naomi S. Rajapaksa, Yun-Xing Cheng, Wei Li, Daniel G.M. Shore, F. Anthony Romero, Marian C. Bryan
  • Publication number: 20200399274
    Abstract: Compounds of formula (I) wherein R1, R2, R3, R4, R5 and R6 are as defined herein, and salts thereof, that are useful as JAK kinase inhibitors are described herein. Also provided are pharmaceutical compositions that include such a JAK inhibitor and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.
    Type: Application
    Filed: June 16, 2020
    Publication date: December 24, 2020
    Applicant: Genentech, Inc.
    Inventors: Mark Edward Zak, Naomi S. Rajapaksa, Yun-Xing Cheng, Jessica Grandner, Daniel G.M. Shore, F. Anthony Romero, Marian C. Bryan
  • Publication number: 20200399275
    Abstract: Compounds of formula (I) wherein R1, R2, R3, R4, R5 and R6 are as defined herein, and salts thereof that are useful as JAK kinse inhibitors are described herein. Also provided are pharmaceutical compositions that include such a JAK inhibitor and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.
    Type: Application
    Filed: June 16, 2020
    Publication date: December 24, 2020
    Applicant: Genentech, Inc.
    Inventors: Mark Edward Zak, Naomi S. Rajapaksa, Yun-Xing Cheng, Jessica Grandner, Daniel G.M. Shore, Marian C. Bryan
  • Publication number: 20200165260
    Abstract: Compounds of Formula (00A) and salts thereof, wherein R1, R2 R3, R4 and n are defined herein, are useful as inhibitors of one or more Janus kinases. Also provided are pharmaceutical compositions that include a compound of Formula (00A) and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.
    Type: Application
    Filed: January 30, 2020
    Publication date: May 28, 2020
    Applicant: Genentech, Inc.
    Inventors: Yun-Xing Cheng, Paul Gibbons, Terry Kellar, Wei Li, Rohan Mendonca, Po-wai Yuen, Mark Edward Zak, Lei Zhang
  • Publication number: 20190337946
    Abstract: Triazolopyridine compounds that are inhibitors of JAK kinase, such as JAK1, compositions containing these compounds and methods for treating diseases mediated by a JAK kinase. In particular, provided are compounds of formula (I), stereoisomers, tautomers, solvates, prodrugs or pharmaceutically acceptable salts thereof, where R1a, R1b, R1c, R2, R3, R4 and R5 are defined herein, pharmaceutical compositions comprising the compound and a pharmaceutically acceptable carrier, adjuvant or vehicle, methods of using the compound or composition in therapy, for example, for treating a disease or condition mediated by a JAK kinase in a patient.
    Type: Application
    Filed: July 18, 2019
    Publication date: November 7, 2019
    Applicant: Genentech, Inc.
    Inventors: Simon Charles Goodacre, Nicholas Charles Ray, Mark Edward Zak, Yun-Xing Cheng, Wei Li
  • Publication number: 20190322661
    Abstract: Compounds of Formula (00A) and methods of use as Janus kinase inhibitors are described herein.
    Type: Application
    Filed: June 11, 2019
    Publication date: October 24, 2019
    Applicant: Genentech, Inc.
    Inventors: Mark Edward Zak, Nicholas Charles Ray, Simon Charles Goodacre, Rohan Mendonca, Terry Kellar, Yun-Xing Cheng, Wei Li, Po-wai Yuen
  • Patent number: 10189836
    Abstract: Compounds of Formula (I) and methods of use as Janus kinase inhibitors are described herein.
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: January 29, 2019
    Assignee: Genentech, Inc.
    Inventors: Yun-Xing Cheng, Rongbao Hua, Terry Kellar, Wei Li, Paul Gibbons, Mark Edward Zak
  • Publication number: 20180327402
    Abstract: Provided are triazolopyridine compounds that are inhibitors of JAK kinase, such as JAK1, compositions containing these compounds and methods for treating diseases mediated by a JAK kinase. In particular, provided are compounds of formula (I), stereoisomers, tautomers, solvates, prodrugs or pharmaceutically acceptable salts thereof, where R1a, R1b, R1c, R2, R3, R4 and R5 are defined herein, pharmaceutical compositions comprising the compound and a pharmaceutically acceptable carrier, adjuvant or vehicle, methods of using the compound or composition in therapy, for example, for treating a disease or condition mediated by a JAK kinase in a patient.
    Type: Application
    Filed: May 9, 2018
    Publication date: November 15, 2018
    Applicant: Genentech, Inc.
    Inventors: Simon Charles Goodacre, Nicholas Charles Ray, Mark Edward Zak, Yun-Xing Cheng, Wei Li
  • Publication number: 20180305355
    Abstract: Compounds of Formula (00A) and methods of use as Janus kinase inhibitors are described herein.
    Type: Application
    Filed: November 22, 2017
    Publication date: October 25, 2018
    Applicant: Genentech, Inc.
    Inventors: Mark Edward Zak, Nicholas Charles Ray, Simon Charles Goodacre, Rohan Mendonca, Terry Kellar, Yun-Xing Cheng, Wei Li, Po-wai Yuen
  • Publication number: 20180297997
    Abstract: Compounds of Formula (I) and methods of use as Janus kinase inhibitors are described herein.
    Type: Application
    Filed: June 15, 2018
    Publication date: October 18, 2018
    Applicant: Genentech, Inc.
    Inventors: Yun-Xing Cheng, Rongbao Hua, Terry Kellar, Wei Li, Paul Gibbons, Mark Edward Zak
  • Publication number: 20180265515
    Abstract: Compounds of Formula (00A) and salts thereof, wherein R1, R2 R3, R4 and n are defined herein, are useful as inhibitors of one or more Janus kinases. Also provided are pharmaceutical compositions that include a compound of Formula (00A) and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.
    Type: Application
    Filed: May 22, 2018
    Publication date: September 20, 2018
    Applicant: Genentech, Inc.
    Inventors: Yun-Xing Cheng, Paul Gibbons, Terry Kellar, Wei Li, Rohan Mendonca, Po-wai Yuen, Mark Edward Zak, Lei Zhang
  • Publication number: 20180086757
    Abstract: Provided are triazolopyridine compounds that are inhibitors of JAK kinase, such as JAK1, compositions containing these compounds and methods for treating diseases mediated by a JAK kinase. In particular, provided are compounds of formula (I), stereoisomers, tautomers, solvates, prodrugs or pharmaceutically acceptable salts thereof, where R1a, R1b, R1c, R2, R3, R4 and R5 are defined herein, pharmaceutical compositions comprising the compound and a pharmaceutically acceptable carrier, adjuvant or vehicle, methods of using the compound or composition in therapy, for example, for treating a disease or condition mediated by a JAK kinase in a patient.
    Type: Application
    Filed: August 31, 2017
    Publication date: March 29, 2018
    Applicant: Genentech, Inc.
    Inventors: Simon Charles Goodacre, Nicholas Charles Ray, Mark Edward Zak, Yun-Xing Cheng, Wei Li
  • Publication number: 20170145020
    Abstract: Compounds of Formula (00A) and methods of use as Janus kinase inhibitors are described herein.
    Type: Application
    Filed: February 3, 2017
    Publication date: May 25, 2017
    Applicant: Genentech, Inc.
    Inventors: Mark Edward Zak, Nicholas Charles Ray, Simon Charles Goodacre, Rohan Mendonca, Terry Kellar, Yun-Xing Cheng, Wei Li, Po-Wei Yuen
  • Patent number: 9604984
    Abstract: Compounds of Formula (00A) and methods of use as Janus kinase inhibitors are described herein.
    Type: Grant
    Filed: April 26, 2016
    Date of Patent: March 28, 2017
    Assignee: Genentech, Inc.
    Inventors: Mark Edward Zak, Nicholas Charles Ray, Simon Charles Goodacre, Rohan Mendonca, Terry Kellar, Yun-Xing Cheng, Wei Li, Po-Wei Yuen
  • Publication number: 20160237086
    Abstract: Compounds of Formula (00A) and methods of use as Janus kinase inhibitors are described herein.
    Type: Application
    Filed: April 26, 2016
    Publication date: August 18, 2016
    Applicant: Genentech, Inc.
    Inventors: Mark Edward ZAK, Nicholas Charles RAY, Simon Charles GOODACRE, Rohan MENDONCA, Terry KELLAR, Yun-Xing CHENG, Wei LI, Po-Wei YUEN
  • Patent number: 9346815
    Abstract: Compounds of Formula (00A) and methods of use as Janus kinase inhibitors are described herein.
    Type: Grant
    Filed: May 22, 2015
    Date of Patent: May 24, 2016
    Assignee: Genentech, Inc.
    Inventors: Mark Edward Zak, Nicholas Charles Ray, Simon Charles Goodacre, Rohan Mendonca, Terry Kellar, Yun-Xing Cheng, Wei Li, Po-Wai Yuen
  • Publication number: 20150336962
    Abstract: Compounds of Formula (00A) and methods of use as Janus kinase inhibitors are described herein.
    Type: Application
    Filed: May 22, 2015
    Publication date: November 26, 2015
    Applicant: Genentech, Inc.
    Inventors: Mark Edward Zak, Nicholas Charles Ray, Simon Charles Goodacre, Rohan Mendonca, Terry Kellar, Yun-Xing Cheng, Wei Li, Po-Wai Yuen